Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Mai 2015 07:47 ET | Quelle: Islet Sciences, Inc.

Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH

RALEIGH, N.C., May 4, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic...
23. April 2015 12:02 ET | Quelle: Islet Sciences, Inc.

Islet Sciences, Inc. Presented at 50th International Liver Conference

RALEIGH, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
24. März 2015 07:55 ET | Quelle: Islet Sciences, Inc.

Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum

RALEIGH, N.C., March 24, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
09. März 2015 08:07 ET | Quelle: Islet Sciences, Inc.

Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)

RALEIGH, N.C., March 9, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
05. März 2015 08:07 ET | Quelle: Islet Sciences, Inc.

Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD

RALEIGH, N.C., March 5, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
03. März 2015 09:43 ET | Quelle: Islet Sciences, Inc.

Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate

RALEIGH, N.C., March 3, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
09. Februar 2015 08:22 ET | Quelle: Islet Sciences, Inc.

Islet Sciences Engages Investment Bank as Financial Advisor

RALEIGH, N.C., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"), a biopharmaceutical company developing new medicines and technologies for the treatment of...
06. Oktober 2014 08:05 ET | Quelle: Islet Sciences, Inc.

Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate

RALEIGH, N.C., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease,...
01. Oktober 2014 08:10 ET | Quelle: Islet Sciences, Inc.

Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.

RALEIGH, N.C., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences"), a biopharmaceutical company developing new medicines and technologies for the treatment of...
06. August 2014 08:00 ET | Quelle: Islet Sciences, Inc.

Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors

RALEIGH, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic...

Nächste Seite